Ultrafine nanoparticles as multimodal contrast agent

Patent metadata

Field	Value
Publication number	US-10517962-B2
Application number	US-201314394004-A
Country	US
Kind code	B2
Filing date	Apr 12, 2013
Priority date	Apr 13, 2012
Publication date	Dec 31, 2019
Grant date	Dec 31, 2019

Abstract

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

First claim

The invention claimed is:

1. A method for imaging or treating a lung tumor in a subject in need thereof, comprising
administering via the subject's airways, an effective amount of ultrafine nanoparticles as an imaging agent for imaging a tumor that is located in said subject's lungs, as a radiosensitizing agent for treating a tumor that is located in said subject's lungs, or both, said ultrafine nanoparticles having the following properties:
said ultrafine nanoparticles comprise a polyorganosiloxane matrix;
said ultrafine nanoparticles also comprise a chelating agent complexing cations M n+ , M being a rare earth metal, n being an integer between 2 and 4, and optionally doping cations D n+ , D being a rare earth metal other than M, an actinide or a transition element, m being an integer between 2 and 6, and
said ultrafine nanoparticles have a mean diameter having been reduced to a value between 1 and 5 nm by dissolution of all or part of a precursor nanoparticle comprising a core made of a metal oxide or oxyhydroxide of M, and,

irradiating said subject, imaging said subject or both.

2. The method of claim 1 , wherein said ultrafine nanoparticles comprise at least one imaging agent for T 1 MRI imaging, and at least one imaging agent suitable for one of the following imaging techniques:
(i) PET or SPECT scintigraphy,
(ii) fluorescence in the near-infrared range, and
(iii) X-ray tomodensitometry.

3. The method of claim 1 , wherein said M n+ is Gd 3+ and said ultrafine nanoparticles have a relaxivity r1 per ultrafine nanoparticle of between 50 and 5000 mM −1 ·s −1 at 1.4 T.

4. The method of claim 1 , wherein M is a lanthanide.

5. The method of claim 4 , wherein said lanthanide is selected from the group consisting of Dy, Lu, Gd, Ho, Eu, Tb, Nd, Er, Yb and mixtures thereof.

6. The method of claim 1 , wherein each ultrafine nanoparticle is obtained from a precursor nanoparticle comprising:
a core comprising a metal oxide or oxyhydroxide of M, at least partly in cationic form M n+ , n being an integer between 2 and 4, optionally doped with a doping agent D present at least partly in cationic form D m+ , m being an integer between 2 and 6;
at least one coating layer comprising polyorganosiloxanes (POSs);
and, optionally, an overcoating comprising a chelating agent C1 capable of complexing the M n+ cations or a hydrophilic molecule capable of suspending the precursor nanoparticle in an aqueous medium;
said precursor nanoparticle having been subjected to dissolution of the core using a pH-modifying agent or a chelating agent C2, identical to or different than C1, capable of complexing all or part of the M n+ and D m+ cations, such that a mean diameter of the ultrafine nanoparticle thus obtained is reduced to a value of between 1 and 5 nm.

7. The method of claim 1 , wherein said ultrafine nanoparticles further comprise a radioactive isotope that can be used in scintigraphy.

8. The method of claim 7 , wherein said radioactive isotope is a radioactive isotope of In, Tc, Ga, Zr, Y, Cu or Lu.

9. The method of claim 7 , wherein said radioactive isotope is selected from the group consisting of 111 In, 99m Tc, 68 Ga, 64 Cu, 89 Zr, 90 Y and 177 Lu.

10. The method of claim 1 , wherein said ultrafine nanoparticles comprise a T 1 contrast agent suitable for magnetic resonance imaging.

11. The method of claim 1 , wherein the ultrafine nanoparticles comprise a multimodal contrast agent suitable for T 1 MRI imaging, and at least one imaging technique chosen from the group consisting of:
i. PET or SPECT scintigraphy,
ii. fluorescence in the near-infrared range, and
iii. X-ray tomodensitometry.

12. The method of claim 1 , wherein said ultrafine nanoparticles have a Gd weight ratio between 5% and 50%.

13. The method of claim 1 , wherein said chelating agent is selected from the group consisting of diethylenetriaminepentaacetic acid (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA), and derivatives thereof.

14. The method of claim 1 , wherein said ultrafine nanoparticles are administered intranasally or intratracheally.

15. The method of claim 1 , wherein said ultrafine nanoparticles are used both as an imaging agent for MRI of tumors and as a radiosensitizing agent for treating said tumors.

16. A noninvasive method of imaging of a lung tumor in a human patient or an animal patient, comprising the following steps:
(i) administering to said human or animal patient, via the human or animal patient's airways, an effective amount of ultrafine nanoparticles having the following properties:
said ultrafine nanoparticles comprise a polyorganosiloxane matrix;
said ultrafine nanoparticles comprise a chelating agent complexing cations M n+ , M being a rare earth metal, n being an integer between 2 and 4, and optionally doping cations D m+ , D being a rare earth metal other than M, an actinide or a transition element, m being an integer between 2 and 6; and
said ultrafine nanoparticles have a mean diameter having been reduced to a value between 1 and 5 nm by dissolution of all or a part of a precursor nanoparticle comprising a core made of a metal oxide or oxyhydroxide of M; and,

(ii) capturing MRI images using an appropriate MRI sequence, wherein said tumor is located in said human or animal patient's lungs.

17. The method of claim 16 , wherein the ultrafine nanoparticles are administered in the form of an aerosol.

18. A method for monitoring the therapeutic efficacy of a therapeutic treatment of a lung tumor in a human or animal, said method comprising the following steps:
(i) at the initiation of a treatment of a human or animal, administering an effective amount of ultrafine nanoparticles as an imaging agent, said ultrafine nanoparticles having the following properties:
said ultrafine nanoparticles comprise a polyorganosiloxane matrix,
said ultrafine nanoparticles also comprise a chelating agent complexing cations M n+ , M being a rare earth metal, n being an integer between 2 and 4, and optionally doping cations D m+ , D being a rare earth metal other than M, an actinide or a transition element, m being an integer between 2 and 6, and
said ultrafine nanoparticles have a mean diameter having been reduced to a value between 1 and 5 nm by dissolution of all or part of a precursor nanoparticle comprising a core made of a metal oxide or oxyhydroxide of M,

(ii) capturing images of the imaging agent using an appropriate imaging technique in order to visualize the tumor, said tumor being located in the lungs of said human or animal,
(iii) repeating steps (i) and (ii) during the treatment of the human or animal, and
(iv) comparing the change in said tumor during the treatment, thereby deducing the therapeutic efficacy of the treatment.

Assignees

• Univ Claude Bernard Lyon
• Nano H
• Centre National De La Rech Scientifique—Cnrs
• Univ Joseph Fourier
• Univ Grenoble Alpes
• Univ Bordeaux
• Centre Nat Rech Scient

Inventors

• Cremillieux Yannick
• Bianchi Andrea
• Dufort Sandrine
• Coll Jean-Luc
• Lux Francois
• Tillement Olivier

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P11/06

  Antiasthmatics · CPC title

• A61K49/183

  having a (super)(para)magnetic core coated or functionalised with an inorganic material or being composed of an inorganic material entrapping the MRI-active nucleus, e.g. silica core doped with a MRI-active nucleus · CPC title

• A61K49/0032

  Methine dyes, e.g. cyanine dyes · CPC title

• A61K49/0017 Primary

  Fluorescence in vivo · CPC title